Química Nova, 2003 Currently available anti-HIV drugs can be classified into three categories: nucleoside analogue reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs).
Marcus Vinícius Nora de Souza +1 more
doaj +1 more source
Design and in silico screening of analogs of rilpivirine as novel non-nucleoside reverse transcriptase inhibitors (NNRTIs) for antiretroviral therapy [PDF]
, 2021 Jeslyn Wu +5 more
openalex +1 more source
Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants
Clinical and Translational Science, Volume 19, Issue 2, February 2026.ABSTRACT Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe.
Jason D. Kim +4 more
wiley +1 more source
Drug resistance in non-B subtype HIV-1: Impact of HIV-1 reverse transcriptase inhibitors [PDF]
, 2014 Human immunodeficiency virus (HIV) causes approximately 2.5 million new infections every year, and nearly 1.6 million patients succumb to HIV each year.
Arnold, E +10 more
core +2 more sources
HIV Medicine, Volume 27, Issue 2, Page 217-225, February 2026.Abstract Objective Evaluate factors associated with discontinuation of long‐acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) and describe virologic outcomes in those that returned to oral antiretroviral therapy (ART). Methods This is a retrospective cohort study at a single‐centre primary care HIV clinic.
Tali Faggiano +6 more
wiley +1 more source
Lipid Profiles in HIV-Infected Patients Receiving Combination Antiretroviral Therapy: Are Different Antiretroviral Drugs Associated with Different Lipid Profiles? [PDF]
, 2017 Levels of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), and high-density lipoprotein cholesterol (HDL-c), as well as the TC:HDL-c ratio, were compared in patients receiving different antiretroviral therapy ...
d'Arminio Monforte, A. +15 more
core
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens [PDF]
, 2017 López-Cortés, Luis F. et al.[Background and Objective] Significant controversy still exists about ritonavir-boosted protease inhibitor monotherapy (mtPI/rtv) as a simplification strategy that is used up to now to treat patients that have not experienced ...
López-Cortés, Luis F. +2 more
core +1 more source
Bee products as alternatives in the treatment of viral infections
Journal of the Science of Food and Agriculture, Volume 106, Issue 1, Page 33-54, 15 January 2026.Abstract Medicines used in the treatment of viral infections usually reduce symptoms. There is a need to develop drugs that inhibit the viruses and do not merely relieve the symptoms. Natural bee products possess many pharmacological properties and are widely used in folk medicine. There are many studies on the antibacterial effects of bee products but
Michał Otręba +3 more
wiley +1 more source
Alzheimer's &Dementia, Volume 22, Issue 1, January 2026.Abstract INTRODUCTION Cognitive impairment among people with HIV (PWH) remains common, yet underlying mechanisms remain unclear. Alzheimer's disease (AD) is the leading cause of dementia, and blood‐based biomarkers offer a promising diagnostic alternative.
Akarin Hiransuthikul +9 more
wiley +1 more source
Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors [PDF]
, 2016 We analyzed a multi-drug resistant (MR) HIV-1 re- verse transcriptase (RT), subcloned from a patient- derived subtype CRF02 AG, harboring 45 amino acid exchanges, amongst them four thymidine analog mutations (TAMs) relevant for high-level AZT (azi-
Bodem, Jochen +9 more
core +1 more source